Maynard Um
-
-
-
-
-
-
-
Vaxcyte, Inc. (PCVX) Tops Q2 EPS by 7c
-
-
-
-
-
-
-
Vaxcyte (PCVX) Reiterated at Overweight by Cantor Fitzgerald: Next Catalyst in 4Q26
-
-
-
-
-
-
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
-
-
-
-
-
-
Vaxcyte, Inc (PCVX) Appoints Olivier Brandicourt to its Board
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Vaxcyte (PCVX)
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX)
-
-
-
-
-
-
-
Vaxcyte (PCVX) PT Raised to $140 at BofA Securities
-
466,306 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


